Association between the gut microbiota and diabetic nephropathy: a two-sample Mendelian randomization study

References

• Umanath K, Lewis JB. Update on diabetic nephropathy: core curriculum 2018. Am J Kidney Dis. 2018;71(6):884–895. doi:10.1053/j.ajkd.2017.10.026.
   PubMed Web of Science ®Google Scholar
• Valencia WM, Florez H. How to prevent the microvascular complications of type 2 diabetes beyond glucose control. BMJ. 2017;356:i6505. doi:10.1136/bmj.i6505.
   PubMed Web of Science ®Google Scholar
• Li PK, Ma TK. Global impact of nephropathies. Nephrology (Carlton). 2017;22(Suppl 4):9–13. doi:10.1111/nep.13146.
   PubMedGoogle Scholar
• Deng Y, Li N, Wu Y, et al. Global, regional, and national burden of diabetes-related chronic kidney disease from 1990 to 2019. Front Endocrinol (Lausanne). 2021;12:672350. doi:10.3389/fendo.2021.672350.
   PubMed Web of Science ®Google Scholar
• Chiarelli F, Trotta D, Verrotti A, et al. Kidney involvement and disease in patients with diabetes. Panminerva Med. 2003;45(1):23–41.
   PubMed Web of Science ®Google Scholar
• Sun YM, Su Y, Li J, et al. Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochem Biophys Res Commun. 2013;433(4):359–361. doi:10.1016/j.bbrc.2013.02.120.
   PubMed Web of Science ®Google Scholar
• Tervaert TWC, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21(4):556–563. doi:10.1681/asn.2010010010.
   PubMed Web of Science ®Google Scholar
• Hu Q, Jiang L, Yan Q, et al. A natural products solution to diabetic nephropathy therapy. Pharmacol Ther. 2023;241:108314. doi:10.1016/j.pharmthera.2022.108314.
   PubMed Web of Science ®Google Scholar
• Iatcu CO, Steen A, Covasa M. Gut microbiota and complications of type-2 diabetes. Nutrients. 2021;14(1):166. doi:10.3390/nu14010166.
   PubMed Web of Science ®Google Scholar
• Yang G, Wei J, Liu P, et al. Role of the gut microbiota in type 2 diabetes and related diseases. Metabolism. 2021;117:154712. doi:10.1016/j.metabol.2021.154712.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang Z, Zhang X, et al. Alterations of the gut microbiota in patients with diabetic nephropathy. Microbiol Spectr. 2022;10(4):e0032422. doi:10.1128/spectrum.00324-22.
   PubMed Web of Science ®Google Scholar
• Luo L, Luo J, Cai Y, et al. Inulin-type fructans change the gut microbiota and prevent the development of diabetic nephropathy. Pharmacol Res. 2022;183:106367. doi:10.1016/j.phrs.2022.106367.
   PubMed Web of Science ®Google Scholar
• Li YJ, Chen X, Kwan TK, et al. Dietary fiber protects against diabetic nephropathy through short-chain fatty acid-mediated activation of G protein-coupled receptors GPR43 and GPR109A. J Am Soc Nephrol. 2020;31(6):1267–1281. doi:10.1681/asn.2019101029.
   PubMed Web of Science ®Google Scholar
• Lu J, Chen PP, Zhang JX, et al. GPR43 deficiency protects against podocyte insulin resistance in diabetic nephropathy through the restoration of AMPKα activity. Theranostics. 2021;11(10):4728–4742. doi:10.7150/thno.56598.
   PubMed Web of Science ®Google Scholar
• Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. JAMA. 2017;318(19):1925–1926. doi:10.1001/jama.2017.17219.
   PubMed Web of Science ®Google Scholar
• Sanna S, van Zuydam NR, Mahajan A, et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat Genet. 2019;51(4):600–605. doi:10.1038/s41588-019-0350-x.
   PubMed Web of Science ®Google Scholar
• Xu Q, Ni J-J, Han B-X, et al. Causal relationship between gut microbiota and autoimmune diseases: a two-sample mendelian randomization study. Front Immunol. 2021;12:746998. doi:10.3389/fimmu.2021.746998.
   PubMed Web of Science ®Google Scholar
• Sekula P, Del Greco MF, Pattaro C, et al. Mendelian randomization as an approach to assess causality using observational data. J Am Soc Nephrol. 2016;27(11):3253–3265. doi:10.1681/asn.2016010098.
   PubMed Web of Science ®Google Scholar
• MiBioGen consortium. https://mibiogen.gcc.rug.nl/.
   Google Scholar
• Kurilshikov A, Medina-Gomez C, Bacigalupe R, et al. Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat Genet. 2021;53(2):156–165. doi:10.1038/s41588-020-00763-1.
   PubMed Web of Science ®Google Scholar
• Sakaue S, Kanai M, Tanigawa Y, et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet. 2021;53(10):1415–1424. doi:10.1038/s41588-021-00931-x.
   PubMed Web of Science ®Google Scholar
• Palmer TM, Lawlor DA, Harbord RM, et al. Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res. 2012;21(3):223–242. doi:10.1177/0962280210394459.
   PubMed Web of Science ®Google Scholar
• Levin MG, Judy R, Gill D, et al. Genetics of height and risk of atrial fibrillation: a Mendelian randomization study. PLoS Med. 2020;17(10):e1003288. doi:10.1371/journal.pmed.1003288.
   PubMed Web of Science ®Google Scholar
• Gill D, Efstathiadou A, Cawood K, et al. Education protects against coronary heart disease and stroke independently of cognitive function: evidence from Mendelian randomization. Int J Epidemiol. 2019;48(5):1468–1477. doi:10.1093/ije/dyz200.
   PubMed Web of Science ®Google Scholar
• Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512–525. doi:10.1093/ije/dyv080.
   PubMed Web of Science ®Google Scholar
• Burgess S, Scott RA, Timpson NJ, et al. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur J Epidemiol. 2015;30(7):543–552. doi:10.1007/s10654-015-0011-z.
   PubMed Web of Science ®Google Scholar
• Bowden J, Davey Smith G, Haycock PC, et al. Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40(4):304–314. doi:10.1002/gepi.21965.
   PubMed Web of Science ®Google Scholar
• Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol. 2017;46(6):1985–1998. doi:10.1093/ije/dyx102.
   PubMed Web of Science ®Google Scholar
• Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. Stat Med. 2016;35(11):1880–1906. doi:10.1002/sim.6835.
   PubMed Web of Science ®Google Scholar
• Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37(7):658–665. doi:10.1002/gepi.21758.
   PubMed Web of Science ®Google Scholar
• Verbanck M, Chen CY, Neale B, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693–698. doi:10.1038/s41588-018-0099-7.
   PubMed Web of Science ®Google Scholar
• Deng L, Yang Y, Xu G. Empagliflozin ameliorates type 2 diabetes mellitus-related diabetic nephropathy via altering the gut microbiota. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867(12):159234. doi:10.1016/j.bbalip.2022.159234.
   PubMed Web of Science ®Google Scholar
• Kim JE, Nam H, Park JI, et al. Gut microbial genes and metabolism for methionine and branched-chain amino acids in diabetic nephropathy. Microbiol Spectr. 2023;11(2):e0234422. doi:10.1128/spectrum.02344-22.
   PubMed Web of Science ®Google Scholar
• Wu I-W, Lin C-Y, Chang L-C, et al. Gut microbiota as diagnostic tools for mirroring disease progression and circulating nephrotoxin levels in chronic kidney disease: discovery and validation study. Int J Biol Sci. 2020;16(3):420–434. doi:10.7150/ijbs.37421.
   PubMed Web of Science ®Google Scholar
• He J-W, Zhou X-J, Li Y-F, et al. Associations of genetic variants contributing to gut microbiota composition in immunoglobin a nephropathy. mSystems. 2021;6(1):e00819-20 doi:10.1128/mSystems.00819-20.
   Web of Science ®Google Scholar
• Valles-Colomer M, Falony G, Darzi Y, et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol. 2019;4(4):623–632. doi:10.1038/s41564-018-0337-x.
   PubMed Web of Science ®Google Scholar
• Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives. Gut. 2011;60(5):631–637. doi:10.1136/gut.2010.223263.
   PubMed Web of Science ®Google Scholar
• Chen YJ, Lee WH, Ho HJ, et al. An altered fecal microbial profiling in rosacea patients compared to matched controls. J Formos Med Assoc. 2021;120(1 Pt 1):256–264. doi:10.1016/j.jfma.2020.04.034.
   PubMed Web of Science ®Google Scholar
• Hemmings SMJ, Malan-Müller S, van den Heuvel LL, et al. The microbiome in posttraumatic stress disorder and trauma-exposed controls: an exploratory study. Psychosom Med. 2017;79(8):936–946. doi:10.1097/psy.0000000000000512.
   PubMed Web of Science ®Google Scholar
• Ho J, Nicolucci AC, Virtanen H, et al. Effect of prebiotic on microbiota, intestinal permeability, and glycemic control in children with type 1 diabetes. J Clin Endocrinol Metab. 2019;104(10):4427–4440. doi:10.1210/jc.2019-00481.
   PubMed Web of Science ®Google Scholar
• Luo M, Sun M, Wang T, et al. Gut microbiota and type 1 diabetes: a two-sample bidirectional Mendelian randomization study. Front Cell Infect Microbiol. 2023;13:1163898. doi:10.3389/fcimb.2023.1163898.
   PubMed Web of Science ®Google Scholar
• Sakakibara S, Yamauchi T, Oshima Y, et al. Acetic acid activates hepatic AMPK and reduces hyperglycemia in diabetic KK-A(y) mice. Biochem Biophys Res Commun. 2006;344(2):597–604. doi:10.1016/j.bbrc.2006.03.176.
   PubMed Web of Science ®Google Scholar
• Zhou J, Martin RJ, Tulley RT, et al. Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. Am J Physiol Endocrinol Metab. 2008;295(5):E1160–1166. doi:10.1152/ajpendo.90637.2008.
   PubMed Web of Science ®Google Scholar
• Tolhurst G, Heffron H, Lam YS, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012;61(2):364–371. doi:10.2337/db11-1019.
   PubMed Web of Science ®Google Scholar
• Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol. 2015;11(10):577–591. doi:10.1038/nrendo.2015.128.
   PubMed Web of Science ®Google Scholar
• Wong J, Piceno YM, DeSantis TZ, et al. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol. 2014;39(3):230–237. doi:10.1159/000360010.
   PubMed Web of Science ®Google Scholar
• Hu ZB, Lu J, Chen PP, et al. Dysbiosis of intestinal microbiota mediates tubulointerstitial injury in diabetic nephropathy via the disruption of cholesterol homeostasis. Theranostics. 2020;10(6):2803–2816. doi:10.7150/thno.40571.
   PubMed Web of Science ®Google Scholar
• Kimura I, Inoue D, Hirano K, et al. The SCFA receptor GPR43 and energy metabolism. Front Endocrinol (Lausanne). 2014;5:85. doi:10.3389/fendo.2014.00085.
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Saigusa D, Kanemitsu Y, et al. Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease. Nat Commun. 2019;10(1):1835. doi:10.1038/s41467-019-09735-4.
   PubMedGoogle Scholar
• Li P, Wang H, Guo L, et al. Association between gut microbiota and preeclampsia-eclampsia: a two-sample Mendelian randomization study. BMC Med. 2022;20(1):443. doi:10.1186/s12916-022-02657-x.
   PubMed Web of Science ®Google Scholar